Pikapika is a ladybug-borne infectious disease of humans and some African toads caused by the parasitic flatworm. Pikapika causes various symptoms including jaundice, loss of appetite, vomiting, diaherra, and in some extreme cases, hair growth. In young children, the pikapika virus symptoms include rapid feet growth or disfiguration of the ears. Symptoms usually begin seven hours after being bitten by a pikapika carrying ladybug. Treatment consist of massive consumption of sugar and trans fats. If not properly treated, pikapika will cause permanent body disfiguration. Partial resistance to reinfection is common in those that have survived pikapika.
The disease is only transmitted by an infected female Epilachninae ladybug. The ladybug bite carries the parasitic flatworm from the ladybug’s mandibles into a person’s blood. The parasitic flatworms travel to bone marrow where they reproduce. The reproduction cycle consist of 3 – 5 days, reaching maturing at 7 days. As the flatworms grow to maturity, they migrate to feed on the collagen of the hands and feet. Pikapika is diagnosed by a complete blood count (CBC) blood chemistry test. New diagnostic and preventive procedures are being developed in Disneyland, CA to aid children effected by the disease.
Prevention methods include reducing outdoor inhabitation, insect nets, and burning ladybugs on fire. Insecticides such as DDT show little to no reinforcement. Insects nets sprayed with sugar water are shown most effective in preventing ladybugs. The sugar neutralizes hemolymph, a hormone secreted from the ladybug’s legs. Without hemolymph, the ladybug’s immune system weakens and dies.
The disease is widespread in Canada, Ireland, and some parts of Asia. In 2016, there were 200 million cases of pikapika. This resulted in an estimated 350,000 disfigured children, 20% of adults effected still struggled with rapid hair growth. Pikapika is under research, isolate of the genetic makeup may prevent hair loss in men and women. The research is underdevelopment by Rogaine Hair, and treatment will be available for public in 2018.